Campbell & CO Investment Adviser LLC
Position in KRYS — Krystal Biotech, Inc.
CIK 1353570
BALTIMORE, MD
Position in KRYS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,596,804
+$4,292,996 QoQ
Shares Held
17,795
+934.0% QoQ
Ownership
0.060%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in KRYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in KRYS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,596,804 | 17,795 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $303,808 | 1,721 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $273,682 | 1,991 | Shares | Sole | 2025-08-07 | |
| 2024-03-31 | $441,088 | 2,479 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||